Renalytix (RENX) – FDA
-
Renalytix (RENX) Says 1,112 Patient Study Demonstrates Clinical Utility, Care Benefits of KidneyIntelX Risk Stratification in Stage 1 to 3 DKD Patients
-
FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma (RNLX)
-
-
-
Back to RENX Stock Lookup